TCR-based immunotherapy for MPN

Current understanding

To be populated as evidence accumulates.

May 1, 202 — Mutant calreticulin–directed immunotherapies in myeloproliferative neoplasms: cross-connection with car-t-myelofibrosis: Review situates CAR-T and TCR-based approaches as complementary cellular strategies against the mutant CALR neoepitope, both in early clinical testing. (novelty: 3)
2026-05-15 — Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm: Observational discovery study aims to systematically identify MPN-specific antigens and cognate TCRs from bone marrow and blood across MPN subtypes, intended to seed future TCR-engineered adoptive immunotherapy programs (no therapeutic intervention administered). (novelty: 4)